GlassScriptPhysician profile
Suzanne M Strickland
NPI 1104040690
$7,564.48
in general payments reported to CMS, 2019-2025
31 companies · $715 in 2025
The $715 reported for 2025 was more than what a typical Neurology With Special Qualifications In Child Neurology provider received nationally (typical 2025 total: $275).
See the full distribution for Neurology with Special Qualifications in Child Neurology
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,407 · 2020: $1,187 · 2021: $1,122 · 2022: $731 · 2023: $637 · 2024: $765 · 2025: $715.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,118.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,117.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,647.07 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Ucb, INC. | $946.73 | 2019-2025 | Briviact, Fintepla, Nayzilam |
| Sunovion Pharmaceuticals INC. | $632.18 | 2019-2022 | |
| Neurelis, INC. | $574.84 | 2021-2025 | Valtoco |
| Supernus Pharmaceuticals, INC. | $520.05 | 2019-2022 | |
| Greenwich Biosciences, INC. | $502.86 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $446.68 | 2019-2025 | |
| Sk Life Science, INC. | $421.98 | 2020-2025 | |
| Eisai INC. | $381.40 | 2019-2022 | |
| Catalyst Pharmaceuticals, INC. | $280.45 | 2023-2025 | Fycompa |
| Alexion Pharmaceuticals, INC. | $219.32 | 2022-2025 | Ultomiris, Soliris |
| Harmony Biosciences LLC | $216.99 | 2020-2025 | |
| Aquestive Therapeutics, INC. | $142.45 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $112.08 | 2019-2020 | |
| Zogenix INC. | $80.83 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $66.03 | 2021-2022 | |
| Sarepta Therapeutics, INC. | $44.77 | 2020-2023 | Exondys 51 |
| Acadia Pharmaceuticals INC | $40.64 | 2025 | Daybue |
| Neos Therapeutics, LP | $32.08 | 2019 | |
| Otter Pharmaceuticals, LLC | $31.52 | 2025 | Sympazan |
| Genentech USA, INC. | $27.44 | 2024 | Evrysdi |
| Grifols USA, LLC | $25.80 | 2019-2021 | |
| Immedica Pharma US, INC. | $24.93 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.62 | 2022 | |
| Itf Therapeutics LLC | $21.39 | 2025 | |
| Aprecia Pharmaceuticals, LLC | $21.35 | 2020 | |
| Amgen INC. | $21.04 | 2019 | |
| Mallinckrodt Hospital Products INC. | $20.97 | 2020 | |
| Avadel Cns Pharmaceuticals, LLC | $18.29 | 2025 | Lumryz |
| Sanofi Pasteur INC. | $13.13 | 2023 | |
| Travere Therapeutics, INC. | $5.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzanne Strickland listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.